These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

254 related items for PubMed ID: 2313335

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [NHL-BFM 90 therapy study in treatment of malignant non-Hodgkin's lymphoma in children and adolescents. Part 3: An intermediate term analysis of the B-NHL/B-ALL].
    Reiter A, Schrappe M, Yakisan E, Sauter S, Ebell W, Zimmermann M, Hartmann W, Kremens B, Kuhn N, Claviez A.
    Klin Padiatr; 1994; 206(4):242-52. PubMed ID: 7967420
    [Abstract] [Full Text] [Related]

  • 8. [Preliminary study on DHAP regimen for patients with relapsed and refractory non-Hodgkin's lymphoma].
    Li YH, Jiang WQ, Huang HQ, Zhang L, Liu DG, Xu RH, Zhou ZM, Sun XF, Lin TY, Xu GC, He YJ, Guang ZZ.
    Ai Zheng; 2002 Aug; 21(8):900-2. PubMed ID: 12478903
    [Abstract] [Full Text] [Related]

  • 9. Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.
    Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F.
    Eur J Haematol; 2003 Apr; 70(4):219-24. PubMed ID: 12656744
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. High-dose ifosfamide in combination with etoposide and epirubicin (IVE) in the treatment of relapsed/refractory Hodgkin's disease and non-Hodgkin's lymphoma: a report on toxicity and efficacy.
    Proctor SJ, Taylor PR, Angus B, Wood K, Lennard AL, Lucraft H, Carey PJ, Stark A, Iqbal A, Haynes A, Russel N, Leonard RC, Culligan D, Conn J, Jackson GH.
    Eur J Haematol Suppl; 2001 Jul; 64():28-32. PubMed ID: 11486397
    [Abstract] [Full Text] [Related]

  • 15. Sequential studies on the role of mitoxantrone, high-dose cytarabine, and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of refractory non-Hodgkin's lymphoma.
    Ho AD, Del Valle F, Haas R, Engelhard M, Hiddemann W, Rückle H, Schlimok G, Thiel E, Andreesen R, Fiedler W.
    Semin Oncol; 1990 Dec; 17(6 Suppl 10):14-8; discussion 18-9. PubMed ID: 2259918
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
    Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
    Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.